Infectious diseases are a leading cause of death worldwide. Novel therapeutics are urgently required to treat multidrug-resistant organisms such as Mycobacterium tuberculosis and to mitigate morbidity and mortality caused by acute infections such as malaria and dengue fever virus as well as chronic infections such as human immunodeficiency virus-1 and hepatitis B virus.
| INTRODUCTION
Despite decades of intense research, infectious diseases caused by bacteria, viruses, and parasites still account for a quarter of deaths worldwide. They are ranked as the top cause of death in developing countries and as the number one killer of children under the age of 5 years globally (WHO, 2012) . Rising hospitalization rates for cancer, diabetes, and aged care are associated with an increased risk of acquiring infections particularly with multidrug-resistant organisms. This underscores the economic burden of infectious diseases on the public health systems throughout the world (Spellberg et al., 2008) . Frequent epidemic outbreaks and the challenge of the rapid spread of infectious agents around the globe, facilitated by higher travel frequencies, indicate that we are a long way away from winning the battle against infectious disease.
The recent development of the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system as a genome-editing technique has significantly facilitated gene modifications in both pathogen and host cells and enables profound analysis of the molecular mechanisms that are involved in pathogenesis of infection. CRISPR/Cas9 can be utilized in whole genome screens in host and pathogen to identify novel regulator proteins that are central for manifestation of infection and thus present novel therapeutic targets. Furthermore, the CRISPR/Cas9 system has great potential in the development of novel antimicrobials and vaccines and therefore has the ability to open new avenues both for treatment and prevention of infectious diseases.
Although research has already revealed the tremendous assets of CRISPR/Cas9, there is still a lot we have to learn about the system itself in order to fully utilize its potential as a powerful tool in the fight against infectious diseases.
| THE CRISPR/CAS9 SYSTEM-A UNIVERSAL GENE-EDITING TOOL
Twenty years after the discovery of CRISPR in bacteria, Horvath and colleagues provided the first experimental evidence for its role in adaptive bacterial immunity (Barrangou et al., 2007) . In the following years, intense research helped to elucidate the molecular mechanisms of CRISPR-mediated immunity (Brouns et al., 2008; Deltcheva et al., 2011; Garneau et al., 2010; Sapranauskas et al., 2011) and the type II CRISPR system from Streptococcus pyogenes was then adapted for genome editing in mammalian cells (Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013) . Following its discovery and adaptation, CRISPR-mediated genome editing has had tremendous impact on biological research, as it allows for the fast and easy generation of mutant cells and organisms. The CRISPR system is classified into two distinct classes with different types and subtypes. Whereas class I CRISPR systems utilize multiple Cas proteins to degrade foreign nucleic acids, class II systems use a single large Cas endonuclease . The type II CRISPR/Cas9 system only requires two components, namely the Cas9 DNA endonuclease and a small guide RNA (sgRNA), and this simplicity permits its application to almost every organism. This includes not only mammalian cells but also various pathogens such as viruses, bacteria, and fungi (Kennedy et al., 2015; Mali et al., 2013; Vercoe et al., 2013; Vyas, Barrasa, & Fink, 2015) . Mechanistically, the CRISPR/Cas9 works through the action of the Cas9 endonuclease, which is targeted to a particular locus in the genome by a sequence-specific sgRNA. Once a DNA double strand break is induced, repair processes in the cell are triggered to seal the break by a highly error-prone process called non-homologous end joining (NHEJ). During this process, bases are additionally inserted or deleted into the genomic DNA at the break, causing the so-called insertion/ deletion mutants, which often result in frameshift mutations and therefore knockout of the gene of interest (Sander & Joung, 2014) .
However, the basic CRISPR/Cas9 system has been further advanced over the recent years, allowing the introduction of specific mutations and spatiotemporal insertions of small and even large pieces of DNA.
These new developments have been extensively and comprehensively reviewed elsewhere Xue et al., 2016) .
| CRISPR/CAS9 IN FUNCTIONAL GENOMIC SCREENING
Functional genomic screens provide a powerful tool for the identification of critical genes in different cellular pathways. Previous technologies, such as retroviral insertional mutagenesis or RNAi libraries, although promising, did have inherent limitations such as incomplete inactivation or off-target effects (Shalem, Sanjana, & Zhang, 2015) .
In contrast, the CRISPR/Cas9 gene-editing system facilitates highly efficient and robust screening that can reliably identify critical gene products. For example, we and others have shown that the typical validation rate of novel targets identified in whole genome CRISPR/ Cas9 screens ranges around and above 30% (Herold MJ et al., unpublished and Parnas et al., 2015) . CRISPR/Cas9 loss-of-function screens, CRISPR/Cas9-mediated "activation" (CRISPRa) and "repression" (CRISPRi) screens can be performed with minimal off-target effects and allow targeting of non-transcribed genomic regions such as enhancers and promoters, providing a new level of functional genomic screening . Using viral vectors, the sgRNAs are delivered into cells in a pooled library format targeting the whole genome. Alternatively, specific pools of gene subsets can be targeted.
Pooled functional screens are very useful in positive selecting assays, for example, survival screens. It is also possible to use pooled libraries in negative selecting assays such as an assay in which the deletion of a gene leads to cell death. In the latter case, the complexity of the pool (number of genes being targeted) has to be much smaller and higher number of sgRNAs are required per gene . A better option for performing whole genome negative selection screens is the use of arrayed sgRNA libraries. In an arrayed library screen, sgRNAstargeting individual genes are introduced into the cell populations across thousands of wells to cover the whole genome. This setup not only allows negative selecting screens but also many other phenotypic screens (e.g., migration screen, morphology and screen). Thus far, no one has reported on an arrayed whole genome CRISPR screen, but partial genomes have been targeted (Schmidt, Schmid-Burgk, & Hornung, 2015) . Pooled libraries are less costly and less labor intensive compared with arrayed libraries. Additionally, the use of arrayed libraries is restricted by diverse factors associated with assay development and readout (Agrotis & Ketteler, 2015) . However, with growing interest and investment from academia and industry and with the expanding applicability of CRISPR-based genomic screens, arrayed libraries have the potential to develop into valuable genomic tools.
In a conventional loss-of-function (LOF) CRISPR-pooled screen, the gRNA library is transduced into cells that either stably express Cas9 or receive the endonuclease simultaneously on the same viral vector encoding the sgRNAs. The specific cellular phenotype caused by the genetic perturbation is then selected either by positive selection such as mutations that confer resistance to drug treatment or pathogen infection. In negative selection screens, genes essential for cell survival or proliferation that lead to the depletion of cells can be identified . After the selection process, genomic DNA is extracted from the remaining cell population and the sgRNA-encoding regions are amplified by PCR and subjected to "next generation sequencing." Representation of the enriched or depleted sgRNAs, identified by sequencing the sgRNAs, can then be analyzed and correlated with the observed phenotype obtained after the experimental treatment/intervention . The first applications of pooled CRISPR LOF screens-providing proof of principle-identified known resistance genes in human cancer cell lines and mouse embryonic stem cells (Koike-Yusa, Li, Tan, Velasco-Herrera Mdel, & Yusa, 2014; Shalem et al., 2014; Wang, Wei, Sabatini, & Lander, 2014) . In the last 2 years, modified LOF CRISPR screens gained popularity and, amongst others, revealed functional regulatory networks in primary immune cells in response to activation by LPS (Parnas et al., 2015) , led to the identification of novel cancer drug targets (Shi, Wang et al., 2015a) , and were expanded to in vivo screens identifying mutations that drive tumor growth and metastasis to the lung .
As outlined above, the development of variable Cas9 nuclease genomic screens allow us to investigate genetic regulation beyond the coding genome providing a novel way to answer questions about epigenetics and transcriptional regulation. Gilbert et al. utilized CRISPR-mediated repression (CRISPRi) and activation (CRISPRa) tools for functional genomic screening by fusing transcriptional activators or suppressors to enzymatically inactive/dead dCas9. These screens identified genes essential for cell survival, tumor suppression as well as sensitivity to toxins (Gilbert et al., 2014) . In a dCas9/scRNA-mediated activation screen, Zhang and colleagues recruited transcriptional activators such as p65 via scRNAs and identified activation mutants responsible for resistance to the antimelanoma agent Vemurafenib (Konermann et al., 2015) . A very recent study elegantly expanded the utility of CRISPR/Cas9 to elucidate the functions of the noncoding genome: Korkmaz et al. systematically identified noncoding regulatory elements in enhancer regions of TP53 and ESR1-regulated genes .
The above studies demonstrate the great potential of the CRISPR/ Cas9 technology as a screening tool to elucidate cellular pathways, which can further be utilized to dissect factors involved in manifestation and pathophysiology of infectious diseases, both in the pathogen and in the host. In the last 2 years, several groups have already successfully applied CRISPR screens to a variety of pathogenic bacteria, viruses, and parasites (see Table 1 ). Interestingly, the CRISPR/Cas9 system in the gram-negative intracellular pathogen Francisella novicida has been reported to be itself involved in pathogenesis. Francisella represses the production of an immunogenic membrane protein via an antisense RNA-based silencing mechanism that uses two different RNA molecules and the Cas9 protein (Sampson, Saroj, Llewellyn, Tzeng, & Weiss, 2013) . Further studies revealed that this function is critical during infection and mediates antibiotic resistance and inflammasome evasion (Sampson et al., 2014) .
Similar findings were recently observed in Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli where the type I CRISPR/ Cas9 system modulates the endogenous quorum-sensing regulator protein LasR to dampen host immunity and inflammatory responses by evading TLR4 recognition. This potentially suggested a common strategy employed by bacteria to evade host immune function by "self-priming" through endogenous target regulation (Wu & Li, 2016) .
Taken together, these findings represent a paradigm shift in our understanding of the function of CRISPR/Cas9 systems as regulators of bacterial physiology. Therefore, investigating the roles of the CRISPR/ Cas9 system of certain pathogens could lead to a more detailed understanding of virulence and possibly unfold novel strategies for therapeutic interventions.
Based on its high selectivity, CRISPR can also be utilized to specifically target the genome of pathogenic bacteria. Based on early work demonstrating that CRISPR/Cas9 systems can cleave bacterial plasmid DNA (Garneau et al., 2010) , CRISPR was subsequently used to Note. CRISPRa = clustered regularly interspaced short palindromic repeats-mediated activation; CRISPRi = clustered regularly interspaced short palindromic repeats-mediated repression; T3SSs = type 3 secretion systems.
immunize bacteria against the spread of multidrug-resistant plasmids (Vercoe et al., 2013) . Seminal work by Marraffini and colleagues suggests that CRISPR/Cas9 systems could be used for the sequencespecific killing of bacteria (Bikard, Hatoum-Aslan, Mucida, & Marraffini, 2012) . Moreover, Gomaa et al. provided insights of repurposing CRISPR to develop "smart" antibiotics that circumvent multidrug resistance and differentiate between pathogenic and beneficial microorganisms (Gomaa et al., 2014) . However, the delivery of the exogenous CRISPR/Cas9 system into the host bacteria was very inefficient. Citorik et al. and Bikard et al. have greatly improved delivery by using phagemids and thus exploited the ability of bacteriophages to inject their genetic material into the host bacterium (Bikard et al., 2014; Citorik, Mimee, & Lu, 2014) . Encouragingly, the surviving pathogenic bacteria did not evolve resistance but rather received a defective or lacked a CRISPR-Cas system. Furthermore, both groups were able to show moderate, albeit significant reduction of infection using in vivo models of Staphylococcus aureus and enterohemorrhagic E. coli , respectively. In order to circumvent the obstacles of phage administration into infected cells as well as to prevent antibiotic-resistance escape mutants, Yosef et al. recently modified this conventional phage therapy by using lytic phages to sensitize pathogenic bacteria while concomitantly enriching for these sensitized populations. Their proposed approach does not aim to directly kill pathogens, but rather sensitize them to conventional antibiotics. This is achieved by linking a trait that is either beneficial to the bacteria, such as spacers conferring protection from lytic phage or a trait that reverses drug resistance such as spacers targeting resistance genes (Yosef, Manor, Kiro, & Qimron, 2015) .
Taken together, the CRISPR/Cas9 system has the highest potential to be a valuable tool providing tailored antimicrobials for the treatment of multidrug-resistant bacterial infections, thereby targeting pathogenic bacteria "with their own weapons."
The CRISPR/Cas9 system has also been used as a screening platform to advance our understanding of essential bacterial genes that confer survival and chemical vulnerabilities. In a comprehensive
CRISPRi-mediated knock-down screen in Bacillus subtilis, Peters et al.
revealed whole-genome interaction networks and identified complex phenotypes using the technique. The authors propose that this systematic and unbiased approach could be extended to other bacterial species, including pathogenic strains, and be beneficial for the design of novel antibiotic strategies (Peters et al., 2016) . Sepsis remains a significant problem in hospitals around the world.
In recent years, accumulating evidence suggests that targeting the host immune system rather than the systemic underlying infection might hold the key for successful sepsis therapy (Hotchkiss, Coopersmith, McDunn, & Ferguson, 2009 ). In line with this, we recently showed in a clinically relevant "two-hit" model of sepsis that ER-stress-mediated lymphocytopenia could be targeted to improve survival of immunosuppressed mice upon pneumonia challenge (Doerflinger et al., 2016) . We . Given that the CRISPR/Cas9 system originally evolved in bacteria to specifically target invading viruses and foreign DNA, it seems self-evident that this gene-editing tool might be used as a therapeutic tool against viral infections.
Vaccination has been one of the success stories of infectious disease research, and this single intervention protects millions of people from viral and bacterial infections every year. However, high-vaccine manufacturing costs, access to primary health facilities, and logistical issues that impede distribution and maintenance of a "cold chain" are significant obstacles that hinder universal vaccination. Furthermore, antigenic diversity and variation remains a major roadblock in the development of vaccines against many viruses (White et al., 2015).
Yuan et al. reported the use of CRISPR/Cas9 to efficiently edit vaccinia virus to improve its vector function in vaccine development
for infectious diseases and immunotherapies for cancer . Recently, Tang into the host cell, confers resistance to HIV-1 infection (Hou et al., 2015) . Another study has recently generated CCR5 triploid human embryo mutations as a means to hinder HIV infection through this receptor (Kang et al., 2016) . CRISPR/Cas9 whole genome screens could be a very helpful tool to further elucidate the host-pathogen interactions that underlie HIV infection, persistence, and reactivation, which would have the potential to reveal novel therapeutic targets.
Hepatitis B virus infection affects more than 2 billion people worldwide, and although vaccination and current HBV antivirals are highly effective in preventing infection and suppressing viral replication, current existing therapies cannot provide a functional cure for infection. Although the host immune system can effectively control the acute phase of HBV infection, a proportion of HBV carriers develop chronic infection due to a persistent viral minichromosome that takes the form of a covalently closed circular DNA template in hepatocyte reservoirs. The resulting chronic inflammation predisposes infected individuals to cirrhosis and hepatocellular carcinoma (Ebert & Pellegrini, 2016) . The promise of CRISPR/Cas9 as a novel therapeutic strategy for specific disruption of viral covalently closed circular DNA has produced a considerable amount of publications in the last 2 years that provide proof of principle in vitro and in vivo that this approach has the potential to contribute to a functional cure for chronic HBV infection (Dong et al., 2015; Lin et al., 2014; Liu, Hao, Chen, Guo, & Chen, 2015; Kennedy et al., 2015; Wang et al., 2015; Zhen et al., 2015) . In our own studies (Ebert, Allison et al., 2015a; Ebert Preston et al., 2015b) , we were able to eliminate HBV infection in preclinical models using a novel approach of inducing death of HBV-infected showed that ER-associated multi-protein complexes are essential to cleave off the flavivirus structural proteins prM and E for secretion of mature viral particles. Moreover, Ma et al. identified seven host genes that conferred protection against West Nile virus-induced cell death in a CRISPR-based screen (Ma et al., 2015) . CRISPR/Cas9-mediated gene editing has also been achieved in the flavivirus vector Aedes aegypti, paving the way for further functional genomics related studies in this mosquito species with the aim to potentially restrict viral propagation and transmission between vector and human host.
| Parasite and fungal infection-Expanding the application of CRISPR/Cas9
About 3.2 billion people-nearly half of the world's population-are at risk of malaria infection, and more than 200 million malaria cases were reported in 2015 (White et al., 2014) . Approaches to eliminate malaria infections by targeting the transmitting mosquito vector with CRISPR are already under investigation. Gantz et al. revealed a mosquito strain incorporating a synthetic system called a "gene drive"
that passes a malaria-resistance gene on to the mosquitoes' offspring (Gantz et al., 2015) . As malaria parasites are exclusively transmitted by female mosquitoes, Hammond et al. utilized CRISPR to manipulate three different genes in Anopheles gambiae that confer a recessive female-sterility phenotype upon disruption (Hammond et al., 2016) . Therefore, the CRISPR/Cas9-system could be utilized to introduce "gene drives" that suppress mosquito populations to levels that do not support malaria transmission. Studies on Plasmodium falciparum have shown that the malaria parasite itself can also be targeted using CRISPR/Cas9 to further understand pathogenesis and drug resistance (Ghorbal et al., 2014) . The closely related parasite Toxoplasma gondii, one of the most common parasites in the world and the cause of toxoplasmosis, was also shown to be susceptible to genetic manipulation using CRISPR/Cas9 (Sidik, Hackett, Tran, Westwood, & Lourido, 2014; Sugi, Kato, & Weiss, 2016) .
Recently, a genome wide CRISPR/Cas9 screen in Toxoplasma gondii identified essential genes during infection of human host cells and provided proof for the feasibility of CRISPR/Cas9-based screening platforms to expand the horizon of anti-parasitic interventions (Sidik et al., 2016) . Efficient genome editing of parasitic pathogens with CRISPR/Cas9 has also been applied to Leishmania (Sollelis et al., 2015 , Zhang & Matlashewski, 2015 and Trypanosoma (Peng, Kurup, Yao, Minning, & Tarleton, 2015) parasites and open avenues for functional studies to speed up research on leishmaniasis and infectious myocarditis, respectively.
Systemic fungal infections caused by the filamentous fungus
Aspergillus species and the yeast species Cryptococcus and Candida have markedly risen over the past decade, due to an increase in both the aged population and the number of immune-compromised individuals, as well as antifungal-resistant subspecies (Pfaller & Diekema, 2007) . The CRISPR/Cas9 system has been recently applied in genome editing of Candida albicans (Min, Ichikawa, Woolford, & Mitchell, 2016; Vyas et al., 2015) , Aspergillus (Fuller, Chen, Loros, & Dunlap, 2015) , and
Cryptococcus (Wang, Wei et al., 2016a) and has the potential to further uncover the molecular basis of fungal infection and resistance to antifungals (Table 2) .
| CONCLUSION AND FUTURE DIRECTIONS
Infectious diseases still cause significant morbidity and mortality, and novel therapeutic approaches are desperately required to conquer the increasing amount of multidrug-resistant pathogens (Spellberg et al., 2008) . Within only a few years since its development into a genetic tool, the CRISPR/Cas9 system now holds great promise in boosting our chances of controlling and eradicating some of the major global infectious diseases. However, despite the prog- Therefore, in order to fully explore CRISPR/Cas9 in our battle against infections, we first have to gain more insight into its function and regulation.
There have been great improvements in sgRNA/Cas9 design, synthesis, selection, and delivery, and these discoveries continue to build on the specificity and efficiency of CRISPR/Cas9 systems.
However, to progress CRISPR/Cas9 from a genetic research tool to its application in the clinic, improved safety and efficient delivery has to be achieved. In particular, potential off-target effects of the sgRNAs have to be considered and require improved design strategies to avoid unwanted side effects. New delivery methods are being investigated using adeno-associated viral vectors, which compared with lentiviral or adenoviral vectors, have the advantage of low immunogenicity, broad tissue tropism, and minimal insertional mutagenesis (Senis et al., 2014) . However, the small packaging capacity of adenoassociated viral vectors necessitate either modified versions of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) or smaller orthologues such as the recently discovered Cpf1 DNA endonuclease (Zetsche et al., 2015) . Alternatively, it has recently been described that the Cas9 protein could be delivered as a split protein (Chew et al., 2016) . The ongoing quest for more precise, more flexible, and more efficient CRISPR/Cas9 variations will expand the scope for applications in the near future.
The development and refinement of the CRISPR/Cas9 geneediting system also allows for more reliable and highly efficient screening strategies to perform large-scale target identification in the genome and epigenome of both host and pathogen (Xue et al., 2016) . This is of particular interest in order to decipher host-pathogen interactions that underlie factors such as pathogen cell entry, persistence, propagation, and dissemination. Several successful screens have been conducted and shed light on how these host-pathogen interactions during bacterial, viral, or parasitic infection could be targeted for therapeutic intervention (see Table 1 CRISPR/Cas9 technologies also offer the potential to overcome some of our present obstacles in vaccine development, and novel strategies have improved yield and efficiency of vaccine manufacturing (Tang et al., 2016; van der Sanden et al., 2016; Yuan et al., 2015) .
About a fifth of all infectious diseases are vector borne and transmitted by arthropods such as mosquitos and ticks (WHO, 2016) . Therefore, utilizing CRISPR/Cas9 to understand the mechanisms and dynamics of arthropod infection by viruses, such as dengue virus, and parasites, such as Plasmodium, may be a powerful means to study and prevent disease in humans. Vector control by CRISPR/Cas9-mediated "gene drive" has been proposed to interrupt the infectious cycle and would present an alternative strategy that circumvents the need for treating human patients with antimicrobials (Hammond et al., 2016) .
The use of the CRISPR/Cas9 system to act as "smart antimicrobials" in pathogenic bacteria might be an elegant answer to address the rising numbers of multidrug-resistant pathogens. CRISPR/Cas9
can be used to immunize bacteria against the spread of multidrugresistant genes and for the sequence-specific killing of bacteria "by their own weapons" while differentiating between beneficial and pathogenic microorganisms (Bikard et al., 2014; Gomaa et al., 2014 Note. Cas9 = CRISPR-associated protein 9; CRISPR = clustered regularly interspaced short palindromic repeats; HIV = human immunodeficiency virus.
FIGURE 1 Applications of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) in infectious diseases. Within only a few years since its discovery and application as genetic tool, the CRISPR/Cas9 system has found widespread application in infectious disease research. It can be used to directly target known virulence factors of the pathogen as well as host genes conferring pathogenesis during infection or utilized in functional genomic screens to identify novel unknown mediators of infection. CRISPR/Cas9 offers great potential in vaccine production and the development of "smart" antimicrobials and can help in drug target validation in virtually any pathogenic organism. Furthermore, CRISPR/ Cas has been proposed as a promising tool in vector control by introducing "gene drives" that interrupt the infectious cycle been adapted successfully for the use in a broad spectrum of pathogens including bacteria (Mycobacterium tuberculosis), viruses (Hepatitis B virus, Herpes Simplex Virus), parasites (Plasmodium falciparum), and fungi (Candida albicans), and has the potential to uncover novel therapeutic intervention strategies.
However, CRISPR/Cas9 may not be the magic bullet to directly target every pathogen. New gene-editing tools are being promoted and utilized to identify curative interventions for HIV/AIDS. Early findings using CRISPR/Cas9 achieved suppression of virus production and infectivity. Enthusiasm for these outcomes was quickly blunted when it was discovered that double strand repair by non-homologous end joining initiated upon Cas9 cleavage of HIV-1 genomic regions could generate a variety of mutations at the cleavage site that further facilitated virus resistance (Yoder & Bundschuh, 2016) . Therefore, CRISPR/ Cas9 appears to be a double-edged sword in the fight against HIV and targeting the host rather than the highly mutagenic virus may hold the key for future success.
In conclusion, the rapid advance in the area of CRISPR/Cas9 as a genome-editing approach has enabled widespread application to infectious disease research and identification of preventative and therapeutic interventions (see Figure 1) . Therefore, the CRISPR system might be the desperately required weapon in the battle against multidrug-resistant pathogens and epidemic outbreaks that are responsible for a quarter of all deaths worldwide. 
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